HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting
24 Abril 2024 - 9:05AM
Business Wire
The company is developing next generation
lipid-based structures that kill cancer cells and expose cancer to
the immune system
HighField Biopharmaceuticals, a clinical stage immuno-oncology
company using lipid-based therapeutics to treat cancer, announced
today that two HighField abstracts have been accepted with one
poster presentation at the American Society of Clinical Oncology
(ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.
“The ASCO meeting is an important opportunity to share our
unique lipid-based technology with other clinical investigators,”
said Yuhong Xu, Ph.D., Founder and CEO of HighField. “Our
lipid-based structures represent a new generation of therapeutics
targeting the tumor microenvironment for a broad range of
cancers.”
The abstracts reflect Phase 1 clinical trials of two kinds of
lipid-based therapeutics. HFK1 is a drug encapsulated
immunoliposome containing doxorubicin for patients with advanced
refractory solid tumors having HER2 low and HER2+ expression. HER2
expressing solid tumors include breast, bladder, pancreatic,
ovarian, stomach, colon, prostate, lung, uterus and cervix cancers.
HF1K16 is a drug encapsulated immune modulating liposome
containing all-trans retinoic acid (ATRA) for patients with
recurrent and refractory glioma.
HFK1 Poster Presentation
Abstract ID: 3035 Title: The design, preclinical
study and Phase 1 dose escalation of a HER2 targeted immunoliposome
(HF-K1) for HER2 low solid tumor treatment. Presenter: Dr.
Yuhong Xu, Ph.D. Presenter Date: Saturday, June 1, 2024 (9am
-12pm)
HF1K16 Abstract for
Publication Abstract ID.: e14030 Title:
Exploratory phase 1 study of HF1K16 for the treatment of patients
with refractory/recurrent advanced glioma: preliminary efficacy and
mechanism as a monotherapy.
About HighField Biopharmaceuticals
HighField is a clinical stage immuno-oncology company focused on
novel applications of liposome constructs to disrupt existing
immuno-oncology technologies. The company also has a research and
development center and a GMP-compliant production facility.
HighField’s lead clinical development program is HF1K16, a drug
encapsulated immune modulating liposome containing all-trans
retinoic acid targeting myeloid-derived suppressor cells for
treatment of solid tumors. The company’s pipeline also includes
drug encapsulated immunoliposomes for solid tumor cancers. For more
information visit https://highfield.bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424918510/en/
Media Contact: Dan Eramian Opus Biotech Communications
danieleramian@comcast.net 425-306-8716
Business Development Contact: Donald Wyatt HighField
Biopharmaceuticals dwyatt@hf-biopharm.com 206-356-8196